Top Story Today
Hackers Claim They Stole Novo Nordisk's Entire Drug Discovery Playbook
A group calling itself FulcrumSec says it spent two months inside Novo Nordisk's systems, quietly vacuuming up over 1.3 terabytes of data: AI models, 41,000+ proprietary drug compounds, five undisclosed drug programs, manufacturing recipes, and records on 163,000 employees. They demanded $25 million. Novo refused. Now the data is hitting the dark web, and 264 GB is reportedly already available for download. The company calls it a "limited" incident; the hackers say they have everything.
Why it matters: The breach spotlights a massive blind spot across pharma: companies have spent decades securing patient records and manufacturing systems, but AI models, training datasets, and drug discovery pipelines often sit in a poorly guarded gray zone. As the industry bets its future on machine learning, those digital assets may be the most valuable (and vulnerable) things in the building.
Read more →The GLP-1 Wars
Lilly's Cheaper Zepbound Vials Are a Pricing Masterclass, Not a Price Cut
Eli Lilly will sell single-dose Zepbound vials at $449 per month, roughly half the list price of its prefilled pens. The catch: patients draw their own injections, buy only through LillyDirect, and pay cash. Analysts note the vial price is close to Zepbound's estimated net price of $650 after insurer rebates, meaning Lilly's margins barely budge. It looks like a discount. It's really political positioning.
Read more →Novo Nordisk Wants to Sell a Weight-Loss Pill to 300 Million People in China
Novo's CEO says the company will file its oral Wegovy pill in China within months, targeting a market where 538 million adults are overweight or obese and the semaglutide patent already expired. Eli Lilly filed its oral GLP-1 first, 56+ competitors are in development, and generics could arrive by mid-2027. Novo is building a $556 million factory in Tianjin to manufacture locally.
Read more →Pfizer Is Launching 10 Phase 3 Obesity Trials in a Single Year
After its oral GLP-1 pill failed on liver toxicity, Pfizer spent $10 billion acquiring Metsera and its once-monthly injectable. Now it's planning 10 Phase 3 trials in 2026. Mid-stage data showed 12% weight loss, respectable but well short of Zepbound's 20%+. With $17 billion in patent expirations looming, this is Pfizer's most expensive bet in years.
Read more →Clinical Setbacks
Zepzelca Failed the One Test That Could Save Its Approval
Jazz Pharma's lung cancer drug Zepzelca missed its confirmatory trial: patients on monotherapy survived 8.7 months versus 10.7 for the control group. The FDA gave Zepzelca accelerated approval in 2020, and this was the second confirmatory trial to fail. A separate study in first-line maintenance showed a 27% reduction in death risk, giving Jazz a potential lifeline to reposition the drug entirely.
Read more →Sanofi Kills Its Phase 3 Trial in Refractory CIDP After Futility Analysis
An independent committee reviewed Sanofi's MOBILIZE trial of riliprubart in refractory CIDP (a rare nerve disorder where the immune system attacks nerve insulation) and concluded it was unlikely to show efficacy. No safety issues; the drug just didn't work in these patients. The failure casts doubt on complement inhibitors for the toughest neuromuscular cases and may strengthen argenx's competing approach.
Read more →Deals & Industry Moves
Novartis Pours Another $1.4 Billion Into Molecular Glue Degraders
Novartis signed its second deal with Orionis Biosciences, worth up to $1.4 billion, for molecular glue degraders: tiny molecules that trick cells into destroying disease-causing proteins that traditional drugs can't reach. Stacked on partnerships with Monte Rosa, Arvinas, and Dunad, Novartis has now committed over $10 billion in potential milestones across the protein degradation space. No other pharma company comes close.
Read more →Pharma Pledges $300 Billion in U.S. Manufacturing to Dodge 100% Tariffs
Facing threatened tariffs of up to 100% on imported branded drugs, the industry launched its biggest reshoring scramble ever. Lilly committed $27 billion for four new mega-sites, AstraZeneca pledged $50 billion in U.S. manufacturing and R&D, and Pfizer traded lower Medicaid prices for a three-year tariff exemption. The fine print: 80% of active pharmaceutical ingredients are still made overseas, and drug factories take years to build.
Read more →